Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sanofi-Aventis (ADR: SNY) -- Ignore unavailable to you. Want to Upgrade?

To: IKM who wrote (2)	3/23/2005 2:17:16 AM
From: DewDiligence_on_SI	Respond to of 6

I’ve traded SNY a little since the big merger. Even after the recent pop, I think it’s one of the more attractively priced big pharma. SNY has one of the major benefits of NVS --very broad diversification— at a somewhat lower valuation. However, the most attractively priced BP right now in my view is PFE. Talk biotech at tinyurl.com

To: IKM who wrote (2)	11/6/2008 8:56:38 AM
From: zx	Read Replies (1) \| Respond to of 6

In the past month, a once-promising class of prescription medicines has quietly blown up. Just yesterday, Sanofi-Aventis said it was abandoning its drug Acomplia, which had been approved in Europe to treat obesity. Also yesterday, Pfizer said it was giving up on an experimental anti-obesity drug. And last month, Merck scratched its own experimental obesity medicine. All three of the drugs work on the cannabinoid receptors in the brain, which are also targeted by marijuana. Instead of making people hungry, the medicines dampened appetite. The Pfizer and Merck drugs were in late-stage development. Sanofi suspended sales of Acomplia last month, after the European version of the FDA said the drug’s psychiatric side effects outweighed its benefits. At the time, the company called the suspension “temporary” and planned to continue clinical trials of the drug for diabetes and heart disease. Then those clinical trials ran into trouble when French and German regulators called for a halt to the studies. The FDA was concerned about the psychiatric side effects and never granted U.S. approval of the drug, which would have been sold here as Zimulti. All those regulatory issues appear to have spooked Pfizer. In its statement yesterday, the company said: Pfizer believes that the … compound has the potential to be a safe and effective treatment for weight management. However, the Company has decided to discontinue the development program based on changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval.